Tenon Medical shares surged 155.78% to $13.85 Wednesday afternoon after the U.S. Patent and Trademark Office issued a notice of allowance for a patent covering systems, apparatus and methods for stabilizing sacroiliac joints. The decision supports the intellectual property behind Tenon’s sacroiliac joint stabilization platform, potentially strengthening its competitive position as the early-stage medical-device company seeks funding. The move followed disclosures of a $100 million shelf registration and a $4.4 million at-the-market equity program with A.G.P./Alliance Global Partners, as well as a 1-for-35 reverse stock split intended to restore compliance with Nasdaq’s $1 minimum bid-price requirement. Tenon had also reported second-quarter revenue of $1.28 million and earnings per share of negative $12.35, missing estimates of $1.54 million and negative $8.40, respectively. The stock had previously risen 77.06% after hours to $9.65 following the financing disclosures, after gaining 10.77% to $5.45 in regular trading, with volume reaching 11.43 million shares versus an average of 52,310.